Skip to Main Content

Author Details

Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
2005
134
40
PMIDPaper TitleJournal TitlePublished Year
36373784Nuclear pCHK1 as a potential biomarker of increased sensitivity to ATR inhibition.J Pathol2023
37804055Intrinsic cancer cell phosphoinositide 3-kinase δ regulates fibrosis and vascular development in cholangiocarcinoma.Liver Int2023
37349576The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.Commun Biol2023
37306553SIRIUS, Ultra-Scintillating Upconversion Breast Implant for Remote Orthotopic Photodynamic Therapy.ACS Nano2023
37474650Author Correction: The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.Commun Biol2023
37032358Super-enhancer-driven TOX2 mediates oncogenesis in Natural Killer/T Cell Lymphoma.Mol Cancer2023
37463241Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma.Cancer Res2023
36857629A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.Blood2023
36629283Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma.Int J Cancer2023
35163588The <i>H. pylori</i> CagA Oncoprotein Induces DNA Double Strand Breaks through Fanconi Anemia Pathway Downregulation and Replication Fork Collapse.Int J Mol Sci2022
35731212TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling.Mol Cancer Res2022
35503263BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.J Clin Invest2022
356375173D genome organization in the epithelial-mesenchymal transition spectrum.Genome Biol2022
35681502Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC).Cells2022
35954433Refining the Role of Pyruvate Dehydrogenase Kinases in Glioblastoma Development.Cancers (Basel)2022
35879421PI3Kδ activity controls plasticity and discriminates between EMT and stemness based on distinct TGFβ signaling.Commun Biol2022
33478182Erratum: Iyer, A., et al. Integrative Analysis and Machine Learning Based Characterization of Single Circulating Tumor Cells. <i>J. Clin. Med.</i> 2020, <i>9</i>, 1206.J Clin Med2021
33602783SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic <i>PTP4A3</i> through Chromatin Remodeling in t(4;14) Multiple Myeloma.Cancer Res2021
33709473Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.EMBO Mol Med2021
33668151Blocking Aerobic Glycolysis by Targeting Pyruvate Dehydrogenase Kinase in Combination with EGFR TKI and Ionizing Radiation Increases Therapeutic Effect in Non-Small Cell Lung Cancer Cells.Cancers (Basel)2021
33919917Cytoskeletal Dynamics in Epithelial-Mesenchymal Transition: Insights into Therapeutic Targets for Cancer Metastasis.Cancers (Basel)2021
33931443Topography of transcriptionally active chromatin in glioblastoma.Sci Adv2021
33803139Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.Cancers (Basel)2021
34469741GAGE mediates radio resistance in cervical cancers via the regulation of chromatin accessibility.Cell Rep2021
34787118Evolution of CP2 transcription factors in Hexapoda.J Genet2021
34580286Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers.Cell Death Discov2021
34803496MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways.Int J Biol Sci2021
34128838Doxycycline host-directed therapy in human pulmonary tuberculosis.J Clin Invest2021
34322886A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.J Pathol2021
33391524Putting the BRK on breast cancer: From molecular target to therapeutics.Theranostics2021
32370157SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2.Cancers (Basel)2020
31910334USP26 regulates TGF-β signaling by deubiquitinating and stabilizing SMAD7.EMBO Rep2020
31963677Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective.Cancers (Basel)2020
32018052AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.J Thorac Oncol2020
31858684Response to: USP26 regulates TGF-β signalling by deubiquitinating and stabilizing SMAD7; not applicable in glioblastoma.EMBO Rep2020
31830480Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.Life Sci2020
33116254Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma.Sci Rep2020
33334085Correction: Sundararajan, V., et al. SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2. <i>Cancers</i> 2020, <i>12</i>, 1140.Cancers (Basel)2020
33159134Author Correction: Single-cell analysis of EphA clustering phenotypes to probe cancer cell heterogeneity.Commun Biol2020
33103086AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer.iScience2020
32973272OTUD4 enhances TGFβ signalling through regulation of the TGFβ receptor complex.Sci Rep2020
32764731Single-cell analysis of EphA clustering phenotypes to probe cancer cell heterogeneity.Commun Biol2020
32900796Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.Clin Cancer Res2020
32895468Author Correction: Single-cell analysis of EphA clustering phenotypes to probe cancer cell heterogeneity.Commun Biol2020
32667137Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.EMBO Mol Med2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32331451Integrative Analysis and Machine Learning based Characterization of Single Circulating Tumor Cells.J Clin Med2020
32209656Inflammatory and mitogenic signals drive interleukin 23 subunit alpha (IL23A) secretion independent of IL12B in intestinal epithelial cells.J Biol Chem2020
32350249Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.Nat Commun2020
32560395Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique.Cancers (Basel)2020
  • 1 - 50 of 134

Recommended Authors

Children's Hospital of Philadelphia
Career Start Year 2015
Number of shared co-authors 2
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 1
University of Trento
Career Start Year 2012
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 5
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 1
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 2
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 1
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Center for Cancer Research, National Cancer Institute
Career Start Year 2008
Number of shared co-authors 7
University of Basel
Career Start Year 2008
Number of shared co-authors 1
Princess Maxima Center for Pediatric Oncology
Career Start Year 2008
Number of shared co-authors 1
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 4
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 3
University of California san francisco
Career Start Year 2005
Number of shared co-authors 0
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2004
Number of shared co-authors 0
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 0
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 2
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 6
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 13
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 3
Aier Eye Hospital of Wuhan University
Career Start Year 2001
Number of shared co-authors 2
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 16
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 3
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 3
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Career Start Year 1996
Number of shared co-authors 2
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 3
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 0
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 0

Collaborators

National Taiwan University College of Medicine
Co-authored papers 37
Tokyo Medical and Dental University (TMDU)
Co-authored papers 7
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 4
Dasman Diabetes Institute
Co-authored papers 4
Genome Institute of Singapore
Co-authored papers 4
Co-authored papers 3
The Norwegian Radium Hospital, Oslo University Hospital
Co-authored papers 2
Institute for Research in Immunology and Cancer (IRIC), University of Montreal
Co-authored papers 2
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Co-authored papers 2
Institute of Molecular and Cell Biology
Co-authored papers 2
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 2
University of British Columbia
Co-authored papers 2
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
German Cancer Research Center (DKFZ)
Co-authored papers 2
University of British Columbia, and Vancouver General Hospital
Co-authored papers 2
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 2
University of Cambridge
Co-authored papers 1
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 1
California Institute of Technology, USA. institute of technology.edu.
Co-authored papers 1
University of British Columbia
Co-authored papers 1
Co-authored papers 1
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 1
University of Alberta, Canada Cross Cancer Institute
Co-authored papers 1
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 1
Hollings Cancer Center, Medical University of South Carolina
Co-authored papers 1
Fred Hutchinson Cancer Research Center
Co-authored papers 1
Huntsman Cancer Institute, University of Utah
Co-authored papers 1
The University of British Columbia
Co-authored papers 1
University of Cambridge
Co-authored papers 1
Peter MacCallum Cancer Centre
Co-authored papers 1